Become a Member and get exclusive discounted Prices and Deals.

Gastrointestinal Health - H. Pylori Antigen, stool

Doctors DataSKU: A2786
filler

This microorganism, which can be found on the stomach mucosa of infected people, causes very frequent and mostly silent infections that can produce gastritis, gastric ulcers and other serious pathologies. This FDA-cleared, non-invasive test directly measures the antigen in stool (not antibodies) and is used for diagnosing Helicobacter pylori infections. It is also used for monitoring therapeutic efficacy during and after treatment.

...
Full Description

Doctor's Data, Inc. offers the non-invasive HpSA enzyme immunoassay (EIA), an in vitro qualitative procedure for the detection of H. pylori antigens in human stool. Test results can be used to diagnose H. pylori infection, and to monitor patient response during and post therapy. Current scientific literature indicates that testing to confirm eradication should be performed at least four weeks after the completion of therapy.

Find out more

  • View Sample Report
  • Gatrointestinal Health brochure: click here.

    Please contact us at (714) 864-3730 or pe@anti-fragilityhealth.com to order your test.

Gatrointestinal Health

Clinical microbiology plays a crucial role in individual and community health. Because most microbes living on or within the body are beneficial, distinguishing those that are diseaseproducing is a critical function of a clinical microbiology laboratory.

Doctor’s Data bridges traditional clinical microbiology with complementary medicine, providing world-class diagnostic microbiology testing that helps you assess digestive and absorptive functions, detect pathogens or parasites and identify specific bacteria and yeast. Through specimens collected from a variety of body sites and the use of advanced assays and technology, Doctor’s Data determines what microorganisms are present and which may be causing infection. Our painstaking approach can help you select the most appropriate antimicrobial therapy and the comprehensive nature of our testing represents real value for your patients and practice.

Detailed Information

The awareness of Helicobacter pylori in gastrointestinal diseases has increased greatly since Marshall and Warren described the presence of Campylobacter-like organisms in the antral mucosa of patients with histological evidence of antrum gastritis and peptic ulcers, especially duodenal ulcers. The strong correlation between the presence of H. pyloriand histologically confirmed gastritis, peptic ulcer disease and gastric carcinoma, as well as disease resolution after H. pylori eradication, indicates a causative relationship. The ecological niche in humans appears to be restricted to the stomach and duodenum. Patients who harbor the organism are divided into two basic groups: a) colonized and b) infected. Patients who test positive for H. pylori yet have no signs or symptoms of gastrointestinal disease are considered "colonized." Patients who test positive for H. pylori and present with signs or symptoms of gastrointestinal disease are considered "infected." The process by which a colonized individual becomes infected remains unclear. The process by which patients become colonized is also still under investigation. Direct detection requires that an invasive biopsy be taken from the upper gastrointestinal tract. The presence of H. pylori is then confirmed by direct microscopic examination, rapid urease testing or culturing of the organism from the biopsy material. This strategy has the advantage of being able to detect active infections while being highly specific with a very high positive predictive value. The invasive approach subjects the patient to unnecessary risk and discomfort. In contrast, Doctor's Data, Inc. offers the non-invasive HpSA enzyme immunoassay (EIA), an in vitro qualitative procedure for the detection of H. pylori antigens in human stool. Test results can be used to diagnose H. pylori infection, and to monitor patient response during and post therapy. Current scientific literature indicates that testing to confirm eradication should be performed at least four weeks after the completion of therapy.

Usage Directions

Before You Start:

Please read all of the directions, and familiarize yourself with the collection procedures. If you are taking antifungal or antibiotic medications, please finish the course of medication, and then wait three days before starting this collection. Please refrain from taking digestive enzymes, antacids, and aspirin for two days prior to and during the specimen collection, unless otherwise instructed by your physician. Never discontinue prescription medications without first consulting your physician.

Collection Instructions: here

Customer Review